Abstract
In patients with advanced bladder cancer receiving chemotherapy, early assessment of response can avoid unnecessary toxicity. The aim of this study was to assess the role of tumour markers in monitoring response. Serum levels of one or more of markers β human chorionic gonadotrophin (βhCG), carcinoembryomic antigen (CEA), CA125 and CA19.9 were measured in 74 patients with advanced bladder cancer receiving chemotherapy from 1992 to 1997. Forty-three of 74 (58%) of patients had at least one raised marker (1.5 times upper limit of normal range). This was more common in patients with extra-pelvic disease than in those with disease confined to the pelvis (P= 0.002). Thirty-eight of 78 (49%) assessable patients had a radiological response. Neither clinical response (P= 0.81) nor survival (P= 0.16) differed between marker-negative and marker-positive patients. Clinical response was strongly related to marker response in the 35 comparable patients (P= 0.0001). No patient had a clinical response without response of at least one marker. Ninety per cent of patients who achieved a marker response had done so by 8 weeks. Monitoring of tumour markers in patients with advanced bladder cancer can help predict the response to chemotherapy. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Abel PD, Cornell C, Buamah PK and Williams G (1987) Assessment of serum CA19.9 as a tumour marker in patients with carcinoma of the bladder and prostate. Br J Urol 59: 427–429
Dexeus F, Logothetis C, Hossan E and Samuels ML (1986) Carcinoembryonic antigen and beta-human chorionic gonadotropin as serum markers for advanced urothelial malignancies. J Urol 136: 403–407
Fosså SD, Sternberg C, Scher HI, Theodore CH, Mead B, Dearnaley D, Roberts JT and Skovlund E (1996) Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy. Br J Cancer 74: 1655–1659
Guarnaccia S, Pais V, Grous J and Spirito N (1991) Adenocarcinoma of the urachus associated with elevated levels of CA 125. J Urol 145: 140–141
Iles RK, Jenkins BJ, Oliver RT, Blandy JP and Chard T (1989) Beta human chorionic gonadotrophin in serum and urine. A marker for metastatic urothelial cancer. Br J Urol 64: 241–244
Iles RK, Persad R, Trivedi M, Sharma KB, Dickinson A, Smith P and Chard T (1996) Urinary concentration of human chorionic gonadotrophin and its fragments as a prognostic marker in bladder cancer. Br J Urol 77: 61–69
International Germ Cell Cancer Collaborative Group (1997) International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15: 594–603
Loehrer PJ, Sr, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, Raghavan D, Stuart Harris R, Sarosdy MF and Lowe BA et al. (1992) A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study [published erratum appears in J Clin Oncol1993 11: 384. J Clin Oncol 10: 1066–1073
Logothetis CJ, Dexeus FH, Finn L, Sella A, Amato RJ, Ayala AG and Kilbourn RG (1990) A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8: 1050–1055
Marcillac I, Troalen F, Bidart JM, Ghillani P, Ribrag V, Escudier B, Malassagne B, Droz JP, Lhomme C and Rougier P (1992) Free human chorionic gonadotropin beta subunit in gonadal and nongonadal neoplasms. Cancer Res 52: 3901–3907
Marcillac I, Cottu P, Theodore C, Terrier Lacombe MJ, Bellet D and Droz JP (1993) Free hCG-beta subunit as tumour marker in urothelial cancer [letter]. Lancet 341: 1354–1355
Maulard Durdux C, Toubert ME, Hennequin C and Housset M (1997) Serum tissue polypeptide antigen in bladder cancer as a tumor marker: a prospective study. J Clin Oncol 15: 3446–3450
McLoughlin J, Pepera T, Bridger J and Williams G (1991) Serum and urinary levels of beta human chorionic gonadotrophin in patients with transitional cell carcinoma [see comments]. Br J Cancer 63: 822–824
Moutzouris G, Yannopoulos D, Barbatis C, Zaharof A and Theodorou C (1993) Is beta-human chorionic gonadotrophin production by transitional cell carcinoma of the bladder a marker of aggressive disease and resistance to radiotherapy? Br J Urol 72: 907–909
Pectasides D, Bafaloucos D, Antoniou F, Gogou L, Economides N, Varthalitis J, Dimitriades M, Kosmidis P and Athanassiou A (1996) TPA, TATI, CEA, AFP, beta-hCG, PSA, SCC, and CA 19–9 for monitoring transitional cell carcinoma of the bladder. Am J Clin Oncol 19: 271–277
Schmidt A, Bub P, Ruther U and Eisenberger F (1992) Tissue polypeptide antigen for monitoring of advanced bladder cancer after MVEC chemotherapy. Eur Urol 1: 10–12
Sternberg CN, Yagoda A, Scher HI, Watson RC, Herr HW, Morse MJ, Sogani PC, Vaughan ED, Jr Bander N and Weiselberg LR (1988) M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 139: 461–469
Williams G, Colbeck RA and Crawford SM (1990) Treatment of bladder carcinoma using a germ cell chemotherapy protocol. Br J Urol 65: 473–477
Wurzel RS, Yamase HT and Nieh PT (1987) Ectopic production of human chorionic gonadotropin by poorly differentiated transitional cell tumors of the urinary tract. J Urol 137: 502–504
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Cook, A., Huddart, R., Jay, G. et al. The utility of tumour markers in assessing the response to chemotherapy in advanced bladder cancer. Br J Cancer 82, 1952–1957 (2000). https://doi.org/10.1054/bjoc.2000.1147
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1147
Keywords
This article is cited by
-
Serum total hCGβ level is an independent prognostic factor in transitional cell carcinoma of the urothelial tract
British Journal of Cancer (2014)
-
Urine carcinoembryonic antigen levels are more useful than serum levels for early detection of Bilharzial and non-Bilharzial urinary bladder carcinoma: Observations of 43 Egyptian cases
World Journal of Surgical Oncology (2007)